임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

11건 표시

1/2상모집 중· Rheumatoid Arthritis
Phase 1b/2 Study of IV Sarilumab in Adult With RA
리드: 사노피 · 협력: 리제네론
상세 →NCT07704580
1/2상모집 중· Relapse Multiple Myeloma
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
협력: 사노피
상세 →NCT07479979
1/2상모집 중· Advanced Solid Tumor
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
협력: 사노피
상세 →NCT07629960
1/2상모집 중· Geographic Atrophy
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
리드: 사노피
상세 →NCT07215234
1/2상모집 중· Myotonic Dystrophy
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
리드: 사노피
상세 →NCT06844214
1/2상모집 중· Acne
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
리드: 사노피
상세 →NCT07013747
1/2상모집 중· Chlamydia Trachomatis Immunization
Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years
리드: 사노피
상세 →NCT06891417
1/2상모집 중· Acne
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
리드: 사노피
상세 →NCT06316297
1/2상모집 중· Multiple Myeloma
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
협력: 사노피
상세 →NCT06105554
1/2상모집 중· Solid Tumor
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
리드: 사노피
상세 →NCT05584670
1/2상모집 중· Plasma Cell Myeloma Refractory
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
리드: 사노피
상세 →NCT04643002

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.